Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Assessing Cardiovascular Risk in Patients with Diabetes: An Update

Author(s): Christos Damaskos*, Nikolaos Garmpis, Paraskevi Kollia, Georgios Mitsiopoulos, Danai Barlampa, Athanasios Drosos, Alexandros Patsouras, Nikolaos Gravvanis, Vasileios Antoniou, Alexandros Litos and ">Evangelos Diamantis

Volume 16, Issue 4, 2020

Page: [266 - 274] Pages: 9

DOI: 10.2174/1573403X15666191111123622

Price: $65

Abstract

The globalization of the Western lifestyle has resulted in increase of diabetes mellitus, a complex, multifactorial disease. Diabetes mellitus is a condition often related to the disorders of the cardiovascular system. It is well established that three quarters of diabetics, aged over 40, will die from cardiovascular disease and are more likely than non-diabetics to die from their first cardiovascular event. Therefore, it is of paramount importance to individualize treatment via risk stratification. Conditions that increase cardiovascular risk in people with diabetes include age more than 40 years, male gender, history of relative suffering from premature CHD, blood pressure and high LDL levels, presence of microalbuminuria, obstructive sleepapnea, erectile dysfunction and other conditions.

Several models have been developed in order to assess cardiovascular risk in people with and without diabetes. Some of them have been proven to be inadequate while others are widely used for years. An emerging way of risk assessment in patients with diabetes mellitus is the use of biomarkers but a lot of research needs to be done in this field in order to have solid conclusions.

Keywords: Diabetes, cardiovascular risk, risk assessment, biomarkers, low density lipoprotein, coronary heart disease.

Graphical Abstract

[1]
Bertoluci M, Rocha V. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr 2017; 9: 25.
[http://dx.doi.org/10.1186/s13098-017-0225-1]
[2]
Baldwin M. Assessing cardiovascular risk factors and selecting agents to successfully treat patients with type 2 diabetes mellitus. JAOA 2011; 111(2): S2-S12.
[3]
Mansour AA, Douri FA. Diabetes in Iraq: Facing the epidemic. A systematic review. Wulfernia 2015; 22(3): 258-73.
[4]
Lam T, Burns K, Dennis M, Cheung NW, Gunton JE. Assessment of cardiovascular risk in diabetes: Risk scores and provocative testing. World J Diabetes 2015; 6(4): 634-41.
[http://dx.doi.org/10.4239/wjd.v6.i4.634] [PMID: 25987961 ]
[5]
Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1•9 million people. Lancet Diabetes Endocrinol 2015; 3(2): 105-13.
[http://dx.doi.org/10.1016/S2213-8587(14)70219-0] [PMID: 25466521]
[6]
Schofield J, Ho J, Soran H. Cardiovascular risk in type 1 diabetes mellitus. Diabetes Ther 2019; 10(3): 773-89.
[http://dx.doi.org/10.1007/s13300-019-0612-8] [PMID: 31004282 ]
[7]
Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34(39): 3035-87.
[http://dx.doi.org/10.1093/eurheartj/eht108] [PMID: 23996285 ]
[8]
Moser M. The treatment of hypertension A story of myths, misconceptions, controversies and heroics. 2nd Ed. Darien, CT: Le Jacq Communications, Inc. 2002.
[9]
Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967; 20(7): 511-24.
[http://dx.doi.org/10.1016/0021-9681(67)90082-3] [PMID: 6028270 ]
[10]
American Heart Association. Coronary risk handbook: Estimating risk of coronary heart disease in daily practice. New York: American Heart Association 1973.
[11]
Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: The Framingham Study. Am J Cardiol 1976; 38(1): 46-51.
[http://dx.doi.org/10.1016/0002-9149(76)90061-8] [PMID: 132862 ]
[12]
Pickering G. The nature of essential hypertension. London, New York: Grune & Stratton, Inc 1961.
[13]
Brittain E. Probability of coronary heart disease developing. West J Med 1982; 136(1): 86-9.
[PMID: 7072249]
[14]
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.
[http://dx.doi.org/10.1161/01.CIR.97.18.1837] [PMID: 9603539 ]
[15]
D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117(6): 743-53.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.699579] [PMID: 18212285 ]
[16]
Ferket BS, Colkesen EB, Visser JJ, et al. Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 2010; 170(1): 27-40.
[http://dx.doi.org/10.1001/archinternmed.2009.434] [PMID: 20065196 ]
[17]
Damen JAAG, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: Systematic review. BMJ 2016; 353: i2416.
[http://dx.doi.org/10.1136/bmj.i2416] [PMID: 27184143 ]
[18]
Bitton A, Gaziano TA. The Framingham Heart Study’s impact on global risk assessment. Prog Cardiovasc Dis 2010; 53(1): 68-78.
[http://dx.doi.org/10.1016/j.pcad.2010.04.001] [PMID: 20620429 ]
[19]
Lindman AS, Veierod MB, Pedersen JI, et al. The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. Eur J Cardiovasc Prev Rehabil 2007; 14(4): 501-7.
[http://dx.doi.org/10.1097/HJR.0b013e328011490] [PMID: 17667638 ]
[20]
Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Münster (PROCAM) Study. Int J Obes(Lond) 2008; 32(Suppl. 2): S11-6.
[21]
ippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: A validation study. Heart 2008; 94(1): 34-9..
[http://dx.doi.org/10.1136/hrt.2007.134890 ] [PMID: 17916661]
[22]
Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 93(2): 172-6.
[http://dx.doi.org/ 10.1136/hrt.2006.108167] [PMID: 17090561]
[23]
Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007; 30(5): 1292-3.
[http://dx.doi.org/ 10.2337/dc06-1358] [PMID: 17290036]
[24]
Saeed A, Ballantyne CM. Assessing cardiovascular risk and testing in type 2 diabetes. Curr Cardiol Rep 2017; 19: 19.
[http://dx.doi.org/ 10.1007/s11886-017-0831-4] [PMID: 28220465]
[25]
Di Pino A, Urbano F, Piro S, Purrello F, Rabuazzo AM. Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk. World J Diabetes 2016; 7(18): 423-32.
[http://dx.doi.org/ 10.4239/wjd.v7.i18.423] [PMID: 27795816]
[26]
Dixon BS. Is change in albuminuria a surrogate marker for cardiovascular and renal outcomes in type 1 diabetes? Clin J Am Soc Nephrol 2016; 11(11): 1921-3.
[http://dx.doi.org/ 10.2215/CJN.09540916] [PMID: 27797905]
[27]
Carlsson AC. Sundstr€om J, Carrero JJ, et al. Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria. Eur J Prev Cardiol 2017; 24(4): 340-8.
[http://dx.doi.org/ 10.1177/2047487316676134] [PMID: 27794105]
[28]
Yang ZK, Shen Y, Shen WF, et al. Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation end-products levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. Int J Cardiol 2015; 197: 241-7.
[http://dx.doi.org/ 10.1016/j.ijcard.2015.06.003] [PMID: 26142969]
[29]
Berezin AE. Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers. Diabetes Metab Syndr 2019; 13: 995-1003.
[http://dx.doi.org/ 10.1016/j.dsx.2019.01.018] [PMID: 31336558]
[30]
Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: A population-based retrospective cohort study. Lancet 2006; 368(9529): 29-36.
[http://dx.doi.org/10.1016/S0140-6736(06)68967-8] [PMID: 16815377]
[31]
Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332(7533): 73-8.
[http://dx.doi.org/10.1136/bmj.38678.389583.7C] [PMID: 16371403]
[32]
Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010; 303(16): 1610-6.
[http://dx.doi.org/ 10.1001/jama.2010.461] [PMID: 20424251]
[33]
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2014; 129(25)(Suppl. 2): S49-73.
[http://dx.doi.org/10.1161/01.cir.0000437741.48606.98] [PMID: 24222018]
[34]
Qin R, Chen T, Lou Q, Yu D. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. Int J Cardiol 2013; 167(2): 342-50.
[http://dx.doi.org/ 10.1016/j.ijcard.2011.12.100] [PMID: 22251416]
[35]
Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: A meta-analysis and systematic review. Circulation 2015; 132(19): 1795-804.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017926] [PMID: 26311724]
[36]
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: A systematic review and meta-analysis. JAMA 2015; 313(6): 603-15.
[http://dx.doi.org/ 10.1001/jama.2014.18574] [PMID: 25668264]
[37]
Standards of medical care in. diabetes-2016: summary of revisions. Diabetes Care 2016; 39(Suppl. 1): S4-5.
[http://dx.doi.org/10.2337/dc16-S003] [PMID: 26696680 ]
[38]
The Multiple Risk Factor Intervention Trial (MRFIT). Mortality after 16 years for participants randomized to the Multiple Risk Factor Intervention Trial. Circulation 1996; 94(5): 946-51.
[http://dx.doi.org/10.1161/01.CIR.94.5.946] [PMID: 8790030 ]
[39]
Wackers FJ, Young LH, Inzucchi SE, et al. Detection of ischemia in asymptomatic diabetics investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27(8): 1954-61.
[http://dx.doi.org/10.2337/diacare.27.8.1954] [PMID: 15277423 ]
[40]
Maffei E, Seitun S, Nieman K, et al. Assessment of coronary artery disease and calcified coronary plaque burden by computed tomography in patients with and without diabetes mellitus. Eur Radiol 2011; 21(5): 944-53.
[http://dx.doi.org/10.1007/s00330-010-1996-z] [PMID: 21063711]

Rights & Permissions Print Cite
Article Metrics
22
© 2024 Bentham Science Publishers | Privacy Policy